Its clinical utility in early breast cancer has been demonstrated by both the POETIC and WSF ADAPT HR+/HER2- trials, and this is what we aim to further explore through trials such as that proposed in our survey [11,12]. Here, ERBB2 is linked to breast carcinoma.